People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Biotechnology, Software / Tech, Other, Other Technology, Robotics
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eikon Therapeutics, Inc. | — | Biotechnology | Growth/Late | $1.1B | $3.8B | 2021 |
| Hometeam Technologies, Inc. | — | Software / Tech | Series C | $143.1M | $534.7M | 2018 |
| Variant Bio, Inc. | — | Biotechnology | Series D+ | $127.7M | $2.8B | 2019 |
| Pager, Inc. | — | Other | Series B | $74.1M | $264.5M | 2015 |
| AllStripes Research Inc. | — | Other Technology | Series C | $56.0M | $1.0B | 2021 |
| Drone Racing League, Inc. | — | Robotics | Series B | $51.8M | $626.5M | 2019 |
| CareGuardian, Inc. | — | Other Technology | Series B | $35.3M | $228.4M | 2015 |
| 3Scan Inc. | — | Other Technology | Series A | $33.7M | $388.4M | 2016 |
| Kallyope, Inc. | — | Biotechnology | Series B | $28.1M | $1.1B | 2015 |
| Authorea, Inc. | — | Other | Seed | $1.6M | $19.2M | 2015 |
Adam Goulburn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adam Goulburn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ann Lamont | 2 | 9 |
| Joshua Wolfe | 2 | 4 |
| THOMAS ETERGINO | 2 | 3 |
| Nabeel Hyatt | 1 | 16 |
| LEON CHEN | 1 | 15 |
| Andrew Firlik | 1 | 14 |
| Todd Kimmel | 1 | 13 |
| Matt Ocko | 1 | 13 |
| Michael O'Donnell | 1 | 11 |
| Brad Gillespie | 1 | 10 |
| John F. Frankel | 1 | 9 |
| Stuart Nagae | 1 | 9 |
| DROR BERMAN | 1 | 8 |
| Josh Wolfe | 1 | 8 |
| Terry McGuire | 1 | 8 |
| Eric Kim | 1 | 7 |
| Tim Kutzkey | 1 | 7 |
| Bob More | 1 | 6 |
| Philip Eytan | 1 | 5 |
| Julie Sunderland | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.